ClinicalTrials.gg
RecruitingNCT06879145Updated Nov 12, 2026

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

A Phase 2/3 interventional study of SHR-A2102 and Adebrelimab in Muscular Invasive Bladder Cancer (MIBC), sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Nov 12, 2026Enrollment updatedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
740
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.

Planned enrollment
10th of 141
740 · median 75
Started
2025
with 28 others
Phase 2/3
5 of 194
5 open now
Primary completion
2031-12
later than 117 of 118 live
Registered
139th of 194
by date

Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 10th largest by planned enrollment of the 141 interventional ones that give a count, is one of 29 that started in 2025, is one of 5 in phase 2/3, reaches primary completion later than 117 of the 118 other live ones, and was the 139th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Urinary Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).

03

Conditions studied

  • Muscular Invasive Bladder Cancer (MIBC)
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-80 years old, gender not limited.
  2. The patient voluntarily joined this study and signed .
  3. score is 0 or 1.
  4. Expected survival period ≥ 2 years.
  5. Pathology and imaging diagnosis of non muscle invasive bladder cancer.
  6. There are assessable lesions that meet the 1.1 criteria.
  7. Enough organ function.

Exclusion criteria

Exclusion Criteria:

  1. Received systemic anti-tumor therapy 4 weeks before starting the study treatment.
  2. The toxicity and/or complications of previous anti-tumor treatments have not recovered to ≤ 1 level.
  3. Subjects known or suspected to have interstitial pneumonia.
  4. Individuals with any active, known or suspected diseases.
  5. There are clinical symptoms or diseases of the heart that have not been well controlled.
  6. Diagnosed with any other malignant tumor.
  7. Subjects who have experienced severe infections within 28 days prior to their first medication use.
  8. History of immunodeficiency.
  9. Use of attenuated within 28 days prior to the first study medication.
  10. Have undergone major surgery within 28 days prior to the first administration of medication.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
740 participants (estimated)

Study arms

  • Experimental
    SHR-A2102 + Adebrelimab Group

    Treatment with SHR-A2102 in combination with a fixed dose of Adebrelimab.

    Drug: SHR-A2102 · Drug: Adebrelimab

  • Active comparator
    Preoperative Chemotherapy Group

    Preoperative chemotherapy with gemcitabine and cisplatin, and postoperative nivolumab treatment for patients with high-risk recurrence.

    Drug: Gemcitabine Hydrochloride for Injection · Drug: Cisplatin Injection · Drug: Nivolumab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Phase II: pCR evaluated by researchers

    Time frame: 3 months after the last subject underwent RC+PLD surgery.

  2. Phase III: EFS assessed by BICR

    Time frame: 5 years after the first medication of the last subject.

  3. Recommended Phase 3 Dose (RP3D)

    Time frame: 3 months after MIBC surgery.

Secondary outcomes

  1. ORR

    Time frame: From first dose to disease progression or death, whichever comes first, up to 3 years.

  2. DCR

    Time frame: From first dose to disease progression or death, whichever comes first, up to 3 years.

  3. pCR

    Time frame: Three months after MIBC surgery.

  4. EFS

    Time frame: From first dose to disease progression or death, whichever comes first, up to 3 years.

  5. DFS

    Time frame: From first dose to disease progression or death, whichever comes first, up to 3 years.

  6. OS

    Time frame: From first dose to disease progression or death, whichever comes first, up to 3 years.

  7. Pathological downstaging (pDS)

    Time frame: 3 months after MIBC surgery.

  8. AE

    Time frame: From Day1 to 90 days after last dose.

07

Study locations

1 of 1 sites recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Dingwei Ye · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2031, 80 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 17, 2025
StartActual
Apr 25, 2025
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
840→740
Nov 12, 2026
Eligibility
7 inclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • Removed- 1.18-80 years old, gender not limited. 2.The patient voluntarily joined this study and signed informed consent 3.ECOG score is 0 or 1 4.Expected survival period ≥ 2 years. 5.Pathology and imaging diagnosis of non metastatic muscle invasive bladder cancer 6.There are assessable lesions that meet the RECIST 1.1 criteria 7. Enough organ function
  • Added18-80 years old, gender not limited.
  • AddedThe patient voluntarily joined this study and signed informed consent.
  • AddedECOG score is 0 or 1.
  • AddedExpected survival period ≥ 2 years.
  • AddedPathology and imaging diagnosis of non metastatic muscle invasive bladder cancer.
  • AddedThere are assessable lesions that meet the RECIST 1.1 criteria.
  • AddedEnough organ function.
Nov 12, 2026
Interventions
Changed SHR-A2102;Adebrelimab→SHR-A2102. Added Drug: Adebrelimab·Drug: Gemcitabine Hydrochloride for Injection·Drug: Cisplatin Injection·Drug: Nivolumab Injection. Arms added: SHR-A2102 + Adebrelimab Group·Preoperative Chemotherapy Group; arms removed: Treatment with SHR-A2102 in combination with a fixed dose of Adebrelimab
Nov 12, 2026
Primary outcomes
2 edited, 1 added
What changed in the outcomes
  • EditedPhase II: pCR evaluated by researchers;Time frame: Three months after the last subject underwent RC+PLD surgery → 3 months after the last subject underwent RC+PLD surgery.
  • EditedPhase III: EFS assessed by BICR;Time frame: 5 years after the first medication of the last subject → 5 years after the first medication of the last subject.
  • AddedRecommended Phase 3 Dose (RP3D)Time frame: 3 months after MIBC surgery.
Nov 12, 2026
Secondary outcomes
1 edited, 7 time frame changed
What changed in the outcomes
  • ChangedBefore R0 resection rateNow Pathological downstaging (pDS)Time frame: One month after the last subject underwent RC+PLD surgery → 3 months after MIBC surgery.
  • Time frameORRfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
  • Time frameDCRfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
  • Time framepCRThree months after MIBC surgery → Three months after MIBC surgery.
  • Time frameEFSfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
  • Time frameDFSfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
  • Time frameOSfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
  • Time frameAEfrom Day1 to 90 days after last dose → From Day1 to 90 days after last dose.
Nov 12, 2026
Contact
Study contact changed: x•••@hengrui.com · •••2973→y•••@hengrui.com · •••2973; added x•••@hengrui.com · •••2973. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Enrollment 840→740
    Eligibility 7 inclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Removed- 1.18-80 years old, gender not limited. 2.The patient voluntarily joined this study and signed informed consent 3.ECOG score is 0 or 1 4.Expected survival period ≥ 2 years. 5.Pathology and imaging diagnosis of non metastatic muscle invasive bladder cancer 6.There are assessable lesions that meet the RECIST 1.1 criteria 7. Enough organ function
    • Added18-80 years old, gender not limited.
    • AddedThe patient voluntarily joined this study and signed informed consent.
    • AddedECOG score is 0 or 1.
    • AddedExpected survival period ≥ 2 years.
    • AddedPathology and imaging diagnosis of non metastatic muscle invasive bladder cancer.
    • AddedThere are assessable lesions that meet the RECIST 1.1 criteria.
    • AddedEnough organ function.
    Primary outcomes 2 edited, 1 added
    What changed in the outcomes
    • EditedPhase II: pCR evaluated by researchers;Time frame: Three months after the last subject underwent RC+PLD surgery → 3 months after the last subject underwent RC+PLD surgery.
    • EditedPhase III: EFS assessed by BICR;Time frame: 5 years after the first medication of the last subject → 5 years after the first medication of the last subject.
    • AddedRecommended Phase 3 Dose (RP3D)Time frame: 3 months after MIBC surgery.
    Secondary outcomes 1 edited, 7 time frame changed
    What changed in the outcomes
    • ChangedBefore R0 resection rateNow Pathological downstaging (pDS)Time frame: One month after the last subject underwent RC+PLD surgery → 3 months after MIBC surgery.
    • Time frameORRfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
    • Time frameDCRfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
    • Time framepCRThree months after MIBC surgery → Three months after MIBC surgery.
    • Time frameEFSfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
    • Time frameDFSfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
    • Time frameOSfrom first dose to disease progression or death, whichever comes first, up to 3 years → From first dose to disease progression or death, whichever comes first, up to 3 years.
    • Time frameAEfrom Day1 to 90 days after last dose → From Day1 to 90 days after last dose.
    Interventions Changed SHR-A2102;Adebrelimab→SHR-A2102. Added Drug: Adebrelimab·Drug: Gemcitabine Hydrochloride for Injection·Drug: Cisplatin Injection·Drug: Nivolumab Injection. Arms added: SHR-A2102 + Adebrelimab Group·Preoperative Chemotherapy Group; arms removed: Treatment with SHR-A2102 in combination with a fixed dose of Adebrelimab
    Contact Study contact changed: x•••@hengrui.com · •••2973→y•••@hengrui.com · •••2973; added x•••@hengrui.com · •••2973. See the current contact
    + 3 other changes: index terms, verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06879145
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Apr 25, 2025
Primary completion
Dec 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Yanyan Lu
Contact
yanyan.lu.yl87@hengrui.com
+86-518-82342973
Xiaoning Han
Contact
xiaoning.han@hengrui.com
+86-518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Notiretatug rezetecan · Adebrelimab

Start the discussion